The U.S. Food and Drug Administration (FDA) and Product Quality Research Institute (PQRI) are organizing a workshop on the Regulatory Framework for Distributed and Point of Care Pharmaceutical Manufacturing: An Opportunity for DM/POC Stakeholder Engagement to be held on November 14-16, 2022 as a virtual event.
Dr. Richard McFarland, ARMI’s Chief Regulatory Officer, will speak on Wednesday, November 16, 2022, on the Design of Quality Systems and Quality Oversight for Cellular and Gene Therapy (CGT) Products under DM/POC Manufacturing Models.
Event Dates:
November 14 – 16, 2022
The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization whose mission is to advance the bioeconomy of the United States.
BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
ARMI BioIndustries is the full-service development and manufacturing operation within the Advanced Regenerative Manufacturing Institute.
NextFab is the first foundry for American biotechnology. The mission of NextFab is to produce technological solutions that help the United States protect against and respond to health-security threats, enhance daily medical care and add to the U.S. bioeconomy.
BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
